Adding the PD-L1 inhibitor avelumab to best supportive care in the maintenance setting yields significant survival benefit compared with best supporting care alone for patients with advanced bladder cancer who have stable disease following first-line platinum-based chemotherapy, an interim analysis of the JAVELIN Bladder 100 study shows.
A modified disposable circumcision suture device facilitates simpler and faster procedure in children, with a relatively lower complication rate and better cosmetic results compared with the conventional dorsal slit technique, according to a recent study.
The minimally invasive water vapour thermal therapy significantly reduced symptoms of benign prostatic hyperplasia (BPH), including lower urinary tract symptoms (LUTS) and urinary flow rate, and the improvements were sustained through to 5 years, according to long-term data released during the American Urological Association (AUA) 2020 Virtual Meeting.
The investigational, highly selective MET inhibitor savolitinib demonstrated encouraging efficacy and safety vs standard-of-care sunitinib in patients with MET-driven*, unresectable and locally advanced, or metastatic papillary renal cell carcinoma (PRCC), according to the phase III SAVOIR trial results presented at ASCO 2020.
The investigational, oral GnRH* receptor antagonist relugolix effectively and rapidly reduced and sustained testosterone to castration levels while exhibiting a favourable safety profile in men with prostate cancer (PCa), a phase II trial has shown.
Prostate-specific membrane antigen (PSMA) PET-CT offers superior accuracy in identifying pelvic nodal or distant-metastatic disease in men with high-risk prostate cancer and may be a suitable replacement for conventional imaging with CT combined with bone scan, according to results of the proPSMA study.